University of Missouri-Columbia; Scientific Founder, Organovo; CSO, Modern Meadow
Dr. Gabor Forgacs is a theoretical physicist turned bioengineer turned innovator and entrepreneur. He is the George H. Vineyard Professor of Biological Physics at the University of Missouri-Columbia, the Executive and Scientific Director of the Shipley Center for Innovation at Clarkson University and scientific founder of Organovo, Inc. and Modern Meadow, Inc. He was trained as a theoretical physicist at the Roland Eotvos University, Budapest, Hungary and the Landau Institute of Theoretical Physics, Moscow, USSR. He also has a degree in biology. His research interests span from topics in theoretical physics to physical mechanisms in early embryonic development. He is the co-author of the celebrated text in the field, “Biological Physics of the Developing Embryo” (Cambridge University Press, 2005) that discusses the fundamental morphogenetic mechanisms evident in early development. These mechanisms are being applied to building living structures of prescribed shape and functionality using bioprinting, a novel tissue engineering technology he pioneered. He is the author of over 160 peer-reviewed scientific articles and 5 books. He has been recognized by numerous awards and citations. In particular, he was named as one of the “100 most innovative people in business in 2010” by FastCompany.
Bioprinting: What, Why, Where
Monday, 9 February 2015 at 09:00
Add to Calendar ▼2015-02-10 18:30:002015-02-10 19:30:00Europe/LondonTitle to be Confirmed.Tissue Engineering and Bioprinting: Research to Commercialization in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com
This talk will give an overview on the use of 3D printing to build biological structures. Despite the fact that the field is young a number of approaches have been developed, such as inkjet, extrusion, acoustic, laser-assisted bioprinting and others. This reflects the diversity of the applications ranging from the deposition of single cells to the printing of organs, and, as a consequence, the fact that no single method can satisfy all needs. In analogy with any printing process, bioprinting requires the bioink, the biopaper and the bioprinter. However, in contrast to the 3D printing of nonliving compositions bioprinting itself does not result in the final product. The true biological structure, such as a tissue forms from the discrete bioink particles post-printing and is governed by complex biological processes with no counterpart in the inanimate world. This sequence of events will be demonstrated through a specific example. We will end with a peak into the future.
Add to Calendar ▼2015-02-09 00:00:002015-02-10 00:00:00Europe/LondonTissue Engineering and Bioprinting: Research to CommercializationTissue Engineering and Bioprinting: Research to Commercialization in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com